English

Allenex jan-jun: 58,6 msek (44,9) net sales

Report this content

Interim report JANUARY – JUNE 2012

For the second quarter April - June

  • Net sales for the quarter were SEK 28.7 million (24.4), an increase of 17.6 percent compared to the same period last year. (Olerup GmbH became a part of the group on June 1, 2011).
  • Operating income (EBIT) for the quarter was SEK 3.1 million (-8.7).
  • Operating margin for the quarter was 11 percent (-35).
  • Earnings after tax for the quarter were SEK 1.7 million (-127.4).
  • Earnings per share for the quarter, basic and diluted, was SEK 0.01 (-2.04).

For the January – June period

  • Net sales for the period was SEK 58.6 million (44.9), an increase of 30.5 percent compared to the same period last year (Olerup GmbH became a part of the group on June 1, 2011).
  • Operating income (EBIT) for the period was SEK 6.1 million (-11.9).
  • Operating margin for the period was 10 percent (-26).
  • Earnings after tax for the period were SEK 1.2 million (-373.6).
  • Earnings per share for the period, basic and diluted, was SEK 0.01 (-6.00).
  • Equity per share was SEK1.86 (11.65).
  • Equity/assets ratio was 62 percent (41).

Significant events in the second quarter

  • In April, Allenex divested its holdings in the associated company Likvor AB for a consideration of SEK 750 thousand. From an accounting perspective the holding was valued at nil, with the transfer amounting to a corresponding gain in the second quarter 2012 for Allenex.
  • In April, Allenex divested its holdings in the associated company Pharmacolog i Uppsala AB for a consideration of SEK 300 thousand. From an accounting perspective the holding was valued at nil, with the transfer amounting to a corresponding gain in the second quarter 2012 for Allenex.
  • From May 1, Olerup GmbH is selling directly to end customers in the Netherlands and Belgium.
  • In June, Tulane University Hospital, New Orleans, USA, commenced a trial on XM-ONE® prior to kidney transplantation. The estimated inclusion period is one year, after which patients will be followed up for 6 months.
  • In June, the University of Miami commenced a clinical trial on XM-ONE ® prior to kidney transplantation. The estimated inclusion period is one year and patients will be followed up for 6 months following transplantation.

CEO Anders Karlsson’s comments on the second quarter 2012:
”Following streamlining of our operations, Allenex is pleased to report positive operating income in 2012 for the second consecutive quarter. Both sales volumes and margins increased compared to the same period last year. Today, Allenex offers an attractive product portfolio providing our customers with quality pre-transplantation diagnostics. We also see synergy effects from the new product line SBT Resolver from Conexio Genomics. During the quarter, we initiated further evaluation of new products and commenced collaborations with leading transplantation centers in the US and Europe.”

For more information please contact:
Anders Karlsson, CEO Allenex AB, ph: +4670-918 00 10, e-mail: anders.karlsson@allenex.se
Yvonne Axelsson, CFO Allenex AB ph: +468-508 939 72, e-mail yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets ActAnd/or the Financial Instruments Trading Act. The information was submitted for publication on August 28, 2012, at 14.00 CET.

Allenex is a life science-company that develop, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.

Tags:

Transplantation Allenex

Documents & Links